Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients

Margot A. Cousin, Eric T. Matey, Patrick R. Blackburn, Nicole J. Boczek, Tammy M. McAllister, Teresa M. Kruisselbrink, Dusica Babovic-Vuksanovic, Konstantinos N Lazaridis, Eric W Klee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: We characterized the pharmacogenomics (PGx) results received by diagnostic odyssey patients as secondary findings during clinical whole exome sequencing (WES) testing as a part of their care in Mayo Clinic's Individualized Medicine Clinic to determine the potential benefits and limitations to this cohort. Methods: WES results on 94 patients included a subset of PGx variants in CYP2C19, CYP2C9, and VKORC1 if identified in the patient. Demographic, phenotypic, and medication usage information was abstracted from patient medical data. A pharmacist interpreted the PGx results in the context of the patients’ current medication use and made therapeutic recommendations. Results: The majority was young with a median age of 10 years old, had neurological involvement in the disease presentation (71%), and was currently taking medications (90%). Of the 94 PGx-evaluated patients, 91% had at least one variant allele reported and 20% had potential immediate implications on current medication use. Conclusion: Due to the disease complexity and medication needs of diagnostic odyssey patients, there may be immediate benefit obtained from early life PGx testing for many and most will likely find benefit in the future. These results require conscientious interpretation and management to be actionable for all prescribing physicians throughout the lifetime of the patient.

Original languageEnglish (US)
Pages (from-to)269-279
Number of pages11
JournalMolecular Genetics and Genomic Medicine
Volume5
Issue number3
DOIs
StatePublished - Jan 1 2017

Fingerprint

Exome
Pharmacogenetics
Precision Medicine
Therapeutic Uses
Pharmacists
Alleles
Demography
Physicians

Keywords

  • Exome sequencing
  • pediatric
  • pharmacogenomics
  • precision medicine
  • secondary findings

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Cousin, M. A., Matey, E. T., Blackburn, P. R., Boczek, N. J., McAllister, T. M., Kruisselbrink, T. M., ... Klee, E. W. (2017). Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. Molecular Genetics and Genomic Medicine, 5(3), 269-279. https://doi.org/10.1002/mgg3.283

Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. / Cousin, Margot A.; Matey, Eric T.; Blackburn, Patrick R.; Boczek, Nicole J.; McAllister, Tammy M.; Kruisselbrink, Teresa M.; Babovic-Vuksanovic, Dusica; Lazaridis, Konstantinos N; Klee, Eric W.

In: Molecular Genetics and Genomic Medicine, Vol. 5, No. 3, 01.01.2017, p. 269-279.

Research output: Contribution to journalArticle

Cousin MA, Matey ET, Blackburn PR, Boczek NJ, McAllister TM, Kruisselbrink TM et al. Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. Molecular Genetics and Genomic Medicine. 2017 Jan 1;5(3):269-279. https://doi.org/10.1002/mgg3.283
Cousin, Margot A. ; Matey, Eric T. ; Blackburn, Patrick R. ; Boczek, Nicole J. ; McAllister, Tammy M. ; Kruisselbrink, Teresa M. ; Babovic-Vuksanovic, Dusica ; Lazaridis, Konstantinos N ; Klee, Eric W. / Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. In: Molecular Genetics and Genomic Medicine. 2017 ; Vol. 5, No. 3. pp. 269-279.
@article{f8c9233ca0f942a09d499a034ce11195,
title = "Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients",
abstract = "Background: We characterized the pharmacogenomics (PGx) results received by diagnostic odyssey patients as secondary findings during clinical whole exome sequencing (WES) testing as a part of their care in Mayo Clinic's Individualized Medicine Clinic to determine the potential benefits and limitations to this cohort. Methods: WES results on 94 patients included a subset of PGx variants in CYP2C19, CYP2C9, and VKORC1 if identified in the patient. Demographic, phenotypic, and medication usage information was abstracted from patient medical data. A pharmacist interpreted the PGx results in the context of the patients’ current medication use and made therapeutic recommendations. Results: The majority was young with a median age of 10 years old, had neurological involvement in the disease presentation (71{\%}), and was currently taking medications (90{\%}). Of the 94 PGx-evaluated patients, 91{\%} had at least one variant allele reported and 20{\%} had potential immediate implications on current medication use. Conclusion: Due to the disease complexity and medication needs of diagnostic odyssey patients, there may be immediate benefit obtained from early life PGx testing for many and most will likely find benefit in the future. These results require conscientious interpretation and management to be actionable for all prescribing physicians throughout the lifetime of the patient.",
keywords = "Exome sequencing, pediatric, pharmacogenomics, precision medicine, secondary findings",
author = "Cousin, {Margot A.} and Matey, {Eric T.} and Blackburn, {Patrick R.} and Boczek, {Nicole J.} and McAllister, {Tammy M.} and Kruisselbrink, {Teresa M.} and Dusica Babovic-Vuksanovic and Lazaridis, {Konstantinos N} and Klee, {Eric W}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/mgg3.283",
language = "English (US)",
volume = "5",
pages = "269--279",
journal = "Molecular genetics & genomic medicine",
issn = "2324-9269",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients

AU - Cousin, Margot A.

AU - Matey, Eric T.

AU - Blackburn, Patrick R.

AU - Boczek, Nicole J.

AU - McAllister, Tammy M.

AU - Kruisselbrink, Teresa M.

AU - Babovic-Vuksanovic, Dusica

AU - Lazaridis, Konstantinos N

AU - Klee, Eric W

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: We characterized the pharmacogenomics (PGx) results received by diagnostic odyssey patients as secondary findings during clinical whole exome sequencing (WES) testing as a part of their care in Mayo Clinic's Individualized Medicine Clinic to determine the potential benefits and limitations to this cohort. Methods: WES results on 94 patients included a subset of PGx variants in CYP2C19, CYP2C9, and VKORC1 if identified in the patient. Demographic, phenotypic, and medication usage information was abstracted from patient medical data. A pharmacist interpreted the PGx results in the context of the patients’ current medication use and made therapeutic recommendations. Results: The majority was young with a median age of 10 years old, had neurological involvement in the disease presentation (71%), and was currently taking medications (90%). Of the 94 PGx-evaluated patients, 91% had at least one variant allele reported and 20% had potential immediate implications on current medication use. Conclusion: Due to the disease complexity and medication needs of diagnostic odyssey patients, there may be immediate benefit obtained from early life PGx testing for many and most will likely find benefit in the future. These results require conscientious interpretation and management to be actionable for all prescribing physicians throughout the lifetime of the patient.

AB - Background: We characterized the pharmacogenomics (PGx) results received by diagnostic odyssey patients as secondary findings during clinical whole exome sequencing (WES) testing as a part of their care in Mayo Clinic's Individualized Medicine Clinic to determine the potential benefits and limitations to this cohort. Methods: WES results on 94 patients included a subset of PGx variants in CYP2C19, CYP2C9, and VKORC1 if identified in the patient. Demographic, phenotypic, and medication usage information was abstracted from patient medical data. A pharmacist interpreted the PGx results in the context of the patients’ current medication use and made therapeutic recommendations. Results: The majority was young with a median age of 10 years old, had neurological involvement in the disease presentation (71%), and was currently taking medications (90%). Of the 94 PGx-evaluated patients, 91% had at least one variant allele reported and 20% had potential immediate implications on current medication use. Conclusion: Due to the disease complexity and medication needs of diagnostic odyssey patients, there may be immediate benefit obtained from early life PGx testing for many and most will likely find benefit in the future. These results require conscientious interpretation and management to be actionable for all prescribing physicians throughout the lifetime of the patient.

KW - Exome sequencing

KW - pediatric

KW - pharmacogenomics

KW - precision medicine

KW - secondary findings

UR - http://www.scopus.com/inward/record.url?scp=85041393431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041393431&partnerID=8YFLogxK

U2 - 10.1002/mgg3.283

DO - 10.1002/mgg3.283

M3 - Article

AN - SCOPUS:85041393431

VL - 5

SP - 269

EP - 279

JO - Molecular genetics & genomic medicine

JF - Molecular genetics & genomic medicine

SN - 2324-9269

IS - 3

ER -